Induced Allosteric Drug Discovery Platform
Provider 
Founded 2015
Sells To Enterprise, Government
Pricing Model Recurring
Ownership Public

Jacobio's induced-allosteric drug discovery platform identifies cryptic allosteric binding sites and converts them into inhibitor programs against undruggable targets.
The induced-allosteric drug discovery platform is Jacobio's core engine for targeting proteins long considered undruggable. It maps allosteric binding pockets and applies structure-based design to develop potent, selective small-molecule inhibitors.
Programs emerging from the platform include the SHP2 inhibitor sitneprotafib, the KRAS G12C inhibitor glecirasib, the pan-KRAS inhibitor JAB-23E73, and inhibitors of Aurora A, BET, and P53 Y220C, several of which have entered global clinical trials or been licensed to partners.
| Attribute | Induced Allosteric Drug Discovery Platform | Allosteric Inhibitor Screening + Synthetic Lethality Discovery Platform | Dynamo Platform | Magellan Platform | Smart Allostery Platform | |
|---|---|---|---|---|---|---|
| Provider | ||||||
| Founded | 2015 | 2020 | 2016 | 2017 | 2017 | |
| Sells To | Enterprise, Government | Enterprise | Enterprise | Enterprise | Enterprise | |
| Pricing Model | Recurring | Recurring, Software | Recurring, Software | Recurring, Software | Recurring, Software | |
| Ownership | Public | Private | Public | Venture Capital | Private Equity, Venture Capital |
Provider 
Founded 2015
Sells To Enterprise, Government
Pricing Model Recurring
Ownership Public
Provider 
Founded 2020
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Private
Provider 
Founded 2016
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Public
Provider 
Founded 2017
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Venture Capital
Provider 
Founded 2017
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Private Equity, Venture Capital